AIM ImmunoTech CEO buys 11,000 shares at $0.21

AIM ImmunoTech Inc. (AIM) reported that its CEO and President, Thomas K. Equels, purchased 11,000 shares of common stock on September 16, 2026, in an open-market or private transaction at $0.21 per share.

Rhea-AI Filing Summary

AIM ImmunoTech Inc. (AIM) reported that its CEO and President, Thomas K. Equels, purchased 11,000 shares of common stock on September 16, 2026, in an open-market or private transaction at $0.21 per share. Following this buy, he directly holds 102,822 common shares, and no Rule 10b5-1 trading plan is reported.

Insider Trade Summary

Net Buyer: 11,000 shares

Net Buy 1 txn

Insider Equels Thomas K

Role CEO & President

Bought 11,000 shs ($2K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	11,000	$0.21	$2K

Holdings After Transaction: Common Stock — 102,822 shares (Direct)

Key Figures

Shares purchased: 11,000 shares Purchase price: $0.21 per share Total purchase value: $2,310 +1 more

4 metrics

Shares purchased 11,000 shares Common stock bought by CEO and President on September 16, 2026

Purchase price $0.21 per share Price paid for AIM ImmunoTech common stock on September 16, 2026

Total purchase value $2,310 11,000 shares purchased at $0.21 per share

Holdings after transaction 102,822 shares AIM ImmunoTech common shares directly owned by the CEO and President after the purchase

Key Terms

open-market or private transaction, Rule 10b5-1 trading plan, common stock

3 terms

open-market or private transaction financial

"The transaction is described as a purchase in an open-market or private transaction."

Rule 10b5-1 trading plan regulatory

"The filing indicates that no Rule 10b5-1 trading plan is reported."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

common stock financial

"The CEO and President acquired shares of the company’s common stock."

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did AIM ImmunoTech Inc. (AIM) report for its CEO?

AIM ImmunoTech reported that CEO and President Thomas K. Equels purchased 11,000 shares of common stock on September 16, 2026, in an open-market or private transaction at $0.21 per share.

How many AIM (AIM ImmunoTech Inc.) shares does the CEO own after this transaction?

After the September 16, 2026 purchase, CEO and President Thomas K. Equels directly owns 102,822 shares of AIM ImmunoTech common stock.

What was the dollar value of the AIM CEO’s recent share purchase?

Thomas K. Equels bought 11,000 shares at $0.21 per share, for a total purchase value of approximately $2,310.

Was the AIM CEO’s share purchase made under a Rule 10b5-1 trading plan?

No. The filing indicates that the Rule 10b5-1 checkbox is not marked, so no Rule 10b5-1 trading plan is reported for this transaction.

What type of security did the AIM CEO purchase in this Form 4?

CEO and President Thomas K. Equels purchased common stock of AIM ImmunoTech Inc., totaling 11,000 shares in an open-market or private transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/17/2026 - 12:01 PM Accepted by SEC EDGAR 09/17/2026 - 12:01 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Equels Thomas K

(Last) (First) (Middle)

2117 SOUTHWEST HIGHWAY 484

(Street)

OCALA FLORIDA 34473

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
AIM ImmunoTech Inc. [ AIM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO & President

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/16/2026		P		11,000	A	$0.21	102,822	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Thomas K Equels	09/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)